Published in Cancer Weekly, August 15th, 2006
According to a report from Australia, "Treatments evaluated for malignant mesothelioma (MM), including chemotherapy, radiotherapy, and surgery are of limited efficacy. Immunotherapy has shown some promise in MM but optimal vaccination conditions are yet to be defined. Autologous tumor vaccines have the advantage of containing both 'self'- and 'neo'-tumor antigens but they are not commonly used in any cancer, and never in MM."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.